BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...and Incyte Corp. (NASDAQ:INCY) have INCAGN1876, and Leap Therapeutics Inc. (NASDAQ:LPTX) has several partnerships testing TRX518...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...TILs or ≥1.35% CD8+ T cells in the tumor center. 2986 Leap Therapeutics Inc. (NASDAQ:LPTX) TRX518...
...blood of solid tumor patients, reduction of circulating Treg numbers was a pharmacodynamic marker of TRX518...
BioCentury | Sep 5, 2016
Company News

Leap Therapeutics, Macrocure deal

...homolog 1 (DKK1) , is in Phase I/II testing for esophageal cancer and cholangiocarcinoma. Leap’s TRX518...
BioCentury | Aug 29, 2016
Company News

Leap merging with Macrocure

...dickkopf homolog 1 (DKK1), is in Phase I/II testing for esophageal cancer and cholangiocarcinoma. Leap's TRX518...
BioCentury | Jun 6, 2016
Clinical News

TRX518: Phase I data

...a single dose of 0.0001-8 mg/kg IV TRX518 led to 4 cases of stable disease. TRX518...
...American Society of Clinical Oncology meeting in Chicago. Leap Therapeutics Inc. , Cambridge, Mass. Product: TRX518...
BioCentury | Jan 22, 2016
Company News

HealthCare Ventures' Leap makes debut

...against Dickkopf homolog 1 (DKK1) in Phase I/II for esophageal cancer and cholangiocarcinoma. GITR had TRX518...
...Leap came after his firm reviewed clinical data for DKN-01 in esophageal cancer and evaluated TRX518's...
BioCentury | Jan 29, 2015
Strategy

PD-1 matchmaking

...NASDAQ:AGEN); Incyte Corp. (NASDAQ:INCY) Cancer Preclin AlphaVax Inc. Cancer Preclin GITR Inc. Cancer Ph I (TRX518...
BioCentury | May 12, 2014
Strategy

Good news for dealmakers

...last week. GITR Inc. says it has the first-in-class molecule in the space. The biotech's TRX518...
BioCentury | Feb 21, 2011
Clinical News

Tolerx preclinical data

...In a mouse model of cancer, a murine analog of TRX518 as monotherapy and in combination...
...Keystone Symposia on Antibodies as Drugs meeting in Keystone. Tolerx Inc. , Cambridge, Mass. Product: TRX518...
BioCentury | Dec 20, 2010
Clinical News

TRX518: Phase I started

...TRX518 over 18 weeks in up to 40 patients. Tolerx Inc. , Cambridge, Mass. Product: TRX518...
Items per page:
1 - 10 of 11